Stereotactic Magnetic Resonance Guided Radiation Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

397 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-22

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.

* The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer.
* Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research study is a feasibility study, which means it is the first-time investigators at this institution are examining this type of MR-guided radiation to treat cancer.

The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option for cancer.

In this research study, the investigators are hoping to determine if adjusting radiation treatments based on daily MRI has a feasible way to deliver radiation for participants with pancreatic, lung or renal cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreas Cancer Lung Cancer Renal Cancer Adrenal Metastases Prostate Cancer Liver Metastases Oligoprogressive Nodal Metastases Metachronous Nodal Metastases Synchronous Nodal Metastases Mesothelioma Spine Metastases Brain Metastases Borderline Resectable Pancreatic Carcinoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Magnetic Resonance Imaging (MRI) MRIdian Linear Accelerator Pancreas Cancer Lung Cancer Renal Cancer Adrenal Metastases Prostate Cancer Liver Metastases Oligoprogressive Metachronous Synchronous Spine Prostate Boost Pelvic Re Irradiation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

All participants will be assigned to one treatment arm only depending on their cancer type, and will be taken off study once treatment and follow up are complete.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pancreatic

SMART will be administered per each individual disease site standards

Group Type EXPERIMENTAL